Hematologic malignancies: Decisive answers for patients
Download now
Fill out the form below to download our quick reference guide to hematologic malignancy testing.
Testing for hematologic malignancies
We’ve compiled our highly curated testing for lymphoid neoplasms, myeloid neoplasms, and multiple myeloma in one place. Browse our full suite of tests and learn about the genes and disease states each is designed to detect.
Our approach to optimized patient care:
- Provides diagnostic, prognostic, and therapeutic insights to direct treatment selection from an array of options, including the latest targeted and immune therapies.
- Identifies distinct lymphoma and myeloid neoplasm subtypes to guide prognosis and treatment personalization for improved efficacy.
- Was developed by and with the expertise of Mayo Clinic geneticists, pathologists, oncologists, hematologists, and variant scientists to align with guidelines of clinical significance.
Get full access to Mayo Clinic expertise
- The Mayo Clinic Molecular Hematopathology Laboratory is led by expert hematopathologists who focus on molecular diagnostics and interpretation of hematologic disorders.
- Our board-certified hematopathologists sign out cases in the context of comprehensive result interpretation of clinically relevant genes. Patient history and other additional testing are also reviewed for a correlated result.
- Our physicians, laboratorians, and genetic counselors are available to answer questions pertaining to testing options, results interpretation, or case review and coordination.
- Our testing specialists and genetic counselors are available to discuss specific cases and verify test coverage.
Highlights
Dr. Dong Chen and Dr. Sounak Gupta joined the “Becker’s Healthcare Podcast” to discuss the molecular testing space and its important role in personalized cancer treatment. Dr. Chen and Dr. Gupta highlighted the importance of selecting the right molecular tests for patients, the impact of genetic testing on cancer diagnosis and treatment, and how Mayo Clinic Laboratories is helping physicians make informed decisions for the best patient outcomes.
David S. Viswanatha, M.D., explains how Mayo Clinic Laboratories' new assay provides rapid, definitive diagnosis of VEXAS, a recently identified syndrome affecting older men. Early diagnosis is key to managing the syndrome, which severely impacts multiple organs and blood.
William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, joins "Answers From the Lab" for his weekly leadership update with host Bobbi Pritt, M.D., interim chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic. In this episode, Dr. Pritt and Dr. Morice discuss their new roles at Mayo Clinic and update listeners on the latest legislative news impacting the laboratory and diagnostic industries. They also highlight the launch of MayoComplete, Mayo Clinic Laboratories’ robust suite of oncology and hematology testing that uses next-generation sequencing to identify and evaluate presence of mutations.
In this month's "Hot Topic," David Viswanatha, M.D., discusses updates to Mayo Clinic's next-generation sequencing (NGS) for myeloid neoplasm evaluation, involving new test targets, the rationale for new genetic regions, alignments with the World Health Organization (WHO) guidelines and germline predisposition targets.
In a world of ever-faster technical change, Mayo Clinic Laboratories is uniquely positioned to innovate. Collaboration with clinicians pinpoints unmet patient needs and facilitates the development of diagnostic testing that provides answers.
Mayo Clinic’s Advanced Diagnostics Laboratory (ADL) is a visionary space designed to foster innovation. The ADL has a direct impact on patient lives, bringing promising tests and services to patients at Mayo and around the world.